Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  12 results for ""Wallemacq C""

Your Filters

Language : french Language : japanese Filter by : Author
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

[Targeting dyslipidaemia in primary prevention of cardiovascular disease].

  • Authors : Scheen A; Service de Diabétologie, Nutrition et Maladies métaboliques, CHU Liège, Belgique.; Wallemacq C

Subjects: Dyslipidemias*/Dyslipidemias*/Dyslipidemias*/drug therapy ; Dyslipidemias*/Dyslipidemias*/Dyslipidemias*/complications ; Cardiovascular Diseases*/Cardiovascular Diseases*/Cardiovascular Diseases*/prevention & control

  • Source: Revue medicale de Liege [Rev Med Liege] 2024 Jun; Vol. 79 (5-6), pp. 385-393.Publisher: Hopital De Baviere Country of Publication: Belgium NLM ID: 0404317 Publication Model: Print Cited Medium: Print ISSN: 0370-629X

Record details

Read More Add to Saved list
×

[First-line treatment of hypercholesterolemia : start with statin monotherapy or ezetimibe-statin combination ?]

  • Authors : Scheen A; Service de Diabétologie, Nutrition et Maladies métaboliques, CHU Liège, Belgique.; Wallemacq C

Subjects: Anticholesteremic Agents*/Anticholesteremic Agents*/Anticholesteremic Agents*/therapeutic use ; Azetidines*/Azetidines*/Azetidines*/therapeutic use ; Hydroxymethylglutaryl-CoA Reductase Inhibitors*/Hydroxymethylglutaryl-CoA Reductase Inhibitors*/Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use

  • Source: Revue medicale de Liege [Rev Med Liege] 2024 Apr; Vol. 79 (4), pp. 202-207.Publisher: Hopital De Baviere Country of Publication: Belgium NLM ID: 0404317 Publication Model: Print Cited Medium: Print ISSN: 0370-629X

Record details

Read More Add to Saved list
×
Academic Journal

[Evolocumab (Repatha®) : new therapy ofhypercholesterolaemia for secondary prevention of atherosclerotic disease].

  • Authors : Scheen A; Service de Diabétologie, Nutrition et Maladies métaboliques, CHU Liège, Belgique.; Wallemacq C

Subjects: Anticholesteremic Agents*/Anticholesteremic Agents*/Anticholesteremic Agents*/therapeutic use ; Hydroxymethylglutaryl-CoA Reductase Inhibitors*/Hydroxymethylglutaryl-CoA Reductase Inhibitors*/Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use ; Cardiovascular Diseases*/Cardiovascular Diseases*/Cardiovascular Diseases*/chemically induced

  • Source: Revue medicale de Liege [Rev Med Liege] 2023 Oct; Vol. 78 (10), pp. 593-600.Publisher: Hopital De Baviere Country of Publication: Belgium NLM ID: 0404317 Publication Model: Print Cited Medium: Print ISSN: 0370-629X

Record details

Read More Add to Saved list
×
Academic Journal

[Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy].

  • Authors : Scheen AJ; Service de Diabétologie, Nutrition et Maladies métaboliques, Département de Médecine interne, CHU Liège, Belgique.; Wallemacq C

Subjects: Cardiovascular Diseases* ; Anticholesteremic Agents*/Anticholesteremic Agents*/Anticholesteremic Agents*/pharmacology ; Anticholesteremic Agents*/Anticholesteremic Agents*/Anticholesteremic Agents*/therapeutic use

  • Source: Revue medicale de Liege [Rev Med Liege] 2022 Dec; Vol. 77 (12), pp. 745-751.Publisher: Hopital De Baviere Country of Publication: Belgium NLM ID: 0404317 Publication Model: Print Cited Medium: Print ISSN: 0370-629X

Record details

Read More Add to Saved list
×
Academic Journal

[Bempedoïc acid, new cholesterol-lowering drug].

  • Authors : Scheen AJ; Service de Diabétologie, Nutrition et Maladies métaboliques , CHU Liège, Belgique.; Paquot N

Subjects: Anticholesteremic Agents*/Anticholesteremic Agents*/Anticholesteremic Agents*/adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors*/Hydroxymethylglutaryl-CoA Reductase Inhibitors*/Hydroxymethylglutaryl-CoA Reductase Inhibitors*/adverse effects ; Pharmaceutical Preparations*

  • Source: Revue medicale de Liege [Rev Med Liege] 2022 Feb; Vol. 77 (2), pp. 124-131.Publisher: Hopital De Baviere Country of Publication: Belgium NLM ID: 0404317 Publication Model: Print Cited Medium: Print ISSN: 0370-629X

Record details

Read More Add to Saved list
×
Academic Journal

[A decade of progress in the management of dyslipidemia].

  • Authors : Wallemacq C; ) Service de Diabétologie, Nutrition et Maladies métaboliques, CHU Liège, Belgique.; Paquot N

Subjects: Anticholesteremic Agents*/Anticholesteremic Agents*/Anticholesteremic Agents*/therapeutic use ; Cardiovascular Diseases* ; Dyslipidemias*/Dyslipidemias*/Dyslipidemias*/drug therapy

  • Source: Revue medicale de Liege [Rev Med Liege] 2020 May; Vol. 75 (5-6), pp. 386-391.Publisher: Hopital De Baviere Country of Publication: Belgium NLM ID: 0404317 Publication Model: Print Cited Medium: Print ISSN: 0370-629X

Record details

Read More Add to Saved list
×
Academic Journal

[Ezetimibe-rosuvastatin fixed-dose combination (Myrosor®)].

  • Authors : Wallemacq C; Service de Diabétologie, Nutrition et Maladies métaboliques, CHU Liège, Belgique.; Scheen AJ

Subjects: Anticholesteremic Agents*/Anticholesteremic Agents*/Anticholesteremic Agents*/administration & dosage ; Ezetimibe*/Ezetimibe*/Ezetimibe*/administration & dosage ; Hydroxymethylglutaryl-CoA Reductase Inhibitors*

  • Source: Revue medicale de Liege [Rev Med Liege] 2020 Apr; Vol. 75 (4), pp. 260-264.Publisher: Hopital De Baviere Country of Publication: Belgium NLM ID: 0404317 Publication Model: Print Cited Medium: Print ISSN: 0370-629X

Record details

Read More Add to Saved list
×
Academic Journal

[Statins and new-onset diabetes : benefit-risk balance].

  • Authors : Wallemacq C; Service de diabétologie, maladies métaboliques et nutrition, Département de médecine interne, Centre hospitalier universitaire de Liège, 4000 Liège, Belgique.

Subjects: Cardiovascular Diseases*/Cardiovascular Diseases*/Cardiovascular Diseases*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/chemically induced ; Hydroxymethylglutaryl-CoA Reductase Inhibitors*/Hydroxymethylglutaryl-CoA Reductase Inhibitors*/Hydroxymethylglutaryl-CoA Reductase Inhibitors*/adverse effects

  • Source: Revue medicale suisse [Rev Med Suisse] 2019 Aug 21; Vol. 15 (659), pp. 1454-1457.Publisher: Médecine et Hygiène Country of Publication: Switzerland NLM ID: 101219148 Publication Model: Print Cited Medium: Print ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

[Management of hypertriglyceridaemia].

  • Authors : Scheen AJ; Service de Diabétologie, Nutrition et Maladies métaboliques, CHU Liège, Belgique.; Wallemacq C

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Fenofibrate*/Fenofibrate*/Fenofibrate*/therapeutic use ; Hypertriglyceridemia*/Hypertriglyceridemia*/Hypertriglyceridemia*/complications

  • Source: Revue medicale de Liege [Rev Med Liege] 2019 Mar; Vol. 74 (3), pp. 167-172.Publisher: Hopital De Baviere Country of Publication: Belgium NLM ID: 0404317 Publication Model: Print Cited Medium: Print ISSN: 0370-629X

Record details

Read More Add to Saved list
×
Academic Journal

[Evolocumab (Repatha®) : a human monoclonal antibody against PCSK9 protein as potent cholesterol-lowering therapy].

  • Authors : Wallemacq C; Service de Diabétologie, Nutrition et Maladies métaboliques, CHU de Liège, Site Sart-Tilman, 4000 Liège, Belgique.

Subjects: Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*therapeutic use ; Anticholesteremic Agents/Anticholesteremic Agents/Anticholesteremic Agents/*therapeutic use ; Hypercholesterolemia/Hypercholesterolemia/Hypercholesterolemia/*drug therapy

  • Source: Revue medicale de Liege [Rev Med Liege] 2017 Nov; Vol. 72 (11), pp. 505-512.Publisher: Hopital De Baviere Country of Publication: Belgium NLM ID: 0404317 Publication Model: Print Cited Medium: Print ISSN: 0370-629X

Record details

Read More Add to Saved list
×
  • 1-10 of  12 results for ""Wallemacq C""